Real-world bleeding risk with ibrutinib

Print Friendly, PDF & Email


Ibrutinib (Imbruvica)
Photo courtesy of Janssen
The Bruton tyrosine kinase inhibitor ibrutinib has been linked to a 20-fold increased risk of major bleeding in blood cancer patients taking concomitant antiplatelet and anticoagulation therapy in a clinical setting. Caution should be used when weighing the risks and benefits of ibrutinib for patients already taking antiplatelet or... [Read Article]
Print Friendly, PDF & Email

Group releases new CLL guidelines

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
Fludarabine, cyclophosphamide, and rituximab are recommended as initial therapy for fit patients with chronic lymphocytic leukemia (CLL) who do not have TP53 disruption, according to new guidelines from the British Society for Haematology. The guidelines update the 2012 recommendations on CLL to include “significant” developments in treatment. The... [Read Article]
Print Friendly, PDF & Email

Team recommends melanoma screening in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Patients with chronic lymphocytic leukemia (CLL) should be routinely monitored for melanoma, according to researchers. A study of 470 CLL patients showed they have a significantly higher risk of invasive melanoma than the general population. Most of the melanomas reported in this study were detected via routine surveillance, and most were discovered... [Read Article]
Print Friendly, PDF & Email

Frequent BCCs linked to blood cancers

Print Friendly, PDF & Email


Woman sunbathing
New research suggests people who develop frequent cases of basal cell carcinoma (BCC) have an increased risk of leukemias, lymphomas, and other cancers. “We discovered that people who develop 6 or more basal cell carcinomas during a 10-year period are about 3 times more likely than the general population to develop other, unrelated... [Read Article]
Print Friendly, PDF & Email

Treatment guidelines for CAR T-cell therapy

Print Friendly, PDF & Email


CAR T cells
Photo from Penn Medicine
Researchers have developed treatment guidelines for pediatric patients receiving chimeric antigen receptor (CAR) T-cell therapy. The guidelines include recommendations for patient selection and consent, treatment details, and advice on managing cytokine release syndrome (CRS) and other adverse events associated with CAR T-cell therapy. The guidelines were published in... [Read Article]
Print Friendly, PDF & Email

Company narrows focus of development for tazemetostat

Print Friendly, PDF & Email


Micrograph showing DLBCL
Epizyme, Inc., has announced its decision to stop developing tazemetostat for use as monotherapy or in combination with prednisolone for patients with diffuse large B-cell lymphoma (DLBCL). However, tazemetostat is still under investigation as a potential treatment for DLBCL as part of other combination regimens. Tazemetostat is an EZH2 inhibitor being developed... [Read Article]
Print Friendly, PDF & Email

Treatment improves PFS in early stage FL

Print Friendly, PDF & Email


Micrograph showing FL
A multidrug regimen can improve upon involved-field radiotherapy (IFRT) in patients with early stage follicular lymphoma (FL), according to research published in the Journal of Clinical Oncology. FL patients who received IFRT plus cyclophosphamide, vincristine, and prednisolone (CVP)—with or without rituximab—had a significant improvement in progression-free survival (PFS) compared to patients who... [Read Article]
Print Friendly, PDF & Email

Adult CCSs report financial hardships

Print Friendly, PDF & Email


I-Chan Huang, PhD
Photo from St. Jude
Children’s Research
Hospital/Peter Barta
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the National Cancer Institute. Researchers analyzed more than 2800 long-term childhood cancer survivors (CCSs) and found that 65% had financial challenges related to their... [Read Article]
Print Friendly, PDF & Email

Drug receives fast track designation for WM

Print Friendly, PDF & Email


Micrograph showing WM
The US Food and Drug Administration (FDA) has granted fast track designation to zanubrutinib for the treatment of Waldenström’s macroglobulinemia (WM). Zanubrutinib (BGB-3111) is a BTK inhibitor being developed by BeiGene to treat various B-cell malignancies. BeiGene is preparing to submit to the FDA, in the first half of 2019, a new... [Read Article]
Print Friendly, PDF & Email

FDA approves biosimilar filgrastim

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy or undergoing bone marrow transplant, acute myeloid leukemia patients receiving induction or consolidation chemotherapy,... [Read Article]
Print Friendly, PDF & Email

PET-guided treatment didn’t improve outcomes

Print Friendly, PDF & Email


PET scan
Image from Jens Langner
In the PETAL trial, treatment intensification based on results of an interim positron emission tomography (PET) scan did not improve survival outcomes for patients with aggressive lymphomas. PET-positive patients did not benefit by switching from R-CHOP to a more intensive chemotherapy regimen. PET-negative patients did not benefit from 2... [Read Article]
Print Friendly, PDF & Email